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Abstract: Steroid sensitive nephrotic syndrome is one of the most common pediatric glomerular
diseases. Unfortunately, it follows a relapsing and remitting course in the majority of cases, with 50%
of all cases relapsing once or even more often. Most children with idiopathic nephrotic syndrome
respond initially to steroid therapy, nevertheless repeated courses for patients with relapses induce
significant steroid toxicity. Patients with frequent relapses or steroid dependency thus require
alternative treatment, such as cyclophosphamide, cyclosporine, tacrolimus, mycophenolate mofetil,
levamisole, or rituximab. To reduce the relapse rate, several drugs have been used. Among these,
levamisole has been considered the least toxic and least expensive therapy. Several randomized
controlled trials (RCT) showed that levamisole is effective in reducing the relapse risk in steroid
sensitive forms of nephrotic syndrome with a low frequency of side effects. Levamisole is a synthetic
imidazothiazole derivative with immune-modulatory properties. In this article, we review recent data
from randomized trials and observational studies to assess the efficacy of levamisole in frequently
relapsing nephrotic syndrome and steroid-dependent nephrotic syndrome.
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1. Introduction
Nephrotic syndrome (NS) occurs in 16 out of 100,000 children in western countries and is one of
the most common renal diseases in the pediatric population [1]. It is characterized by the appearance
of proteinuria (>1 g/m2/day), hypoalbuminemia (<25 g/L), generalized edema and normal glomerular
function. Usually, there is an idiopathic NS (iNS) with two histological subtypes: (1) NS with small
histological changes, so-called minimal change nephrotic syndrome (MCNS); and with more pronounce
histological lesions, (2) focal segmental glomerulosclerosis (FSGS).
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Idiopathic nephrotic syndrome (iNS) seems to be a T-cell-mediated disease. Clinical observations
show that the first episode and relapses often develop after an infection of the upper respiratory tract
or an allergic reaction. In the acute phase of the disease, a shift in lymphocyte population has been
reported [2]. There also seems to be an enhanced type II immunologic reaction in inactive forms of
NS [3]. These findings and others indicate that there has to be an immunologic trigger in patients
with iNS.
Centrally involved in the onset of proteinuria are podocytes [4]. Podocytes are highly specialized,
terminally differentiated cells, forming the glomerular filtration barrier together with the glomerular
basement membrane and glomerular endothelial cells. Effacement of podocyte foot processes can be
seen in electron microscopy, which is the only abnormality seen in MCNS.
Treatment with steroid is still golden standard, and most forms (90%) of NS show remission
within four weeks of treatment with steroids. In cases who respond to steroids, iNS is classified as
steroid-sensitive nephrotic syndrome (SSNS), defined by the International Study of Kidney Disease in
Children (ISKDC) [5].
The overall prognosis of children suffering from NS is good. Usually, the disease generally
disappears at the onset of puberty. Nevertheless, up to 85% develop at least one relapse within the next
five years [6]. Relapse risk generally decreases over time, but is prolonged during adulthood in some
cases [7]. Recent research focuses on factors leading to initiation of iNS, the prediction of recurrence
rate and important factors to reduce the risk of relapse. However, the exact mechanism of iNS are
still elusive.
2. Side Effects of Traditional Immunosuppressive Agents in the Treatment of
Nephrotic Syndrome
Regarding the literature, approximately 30–60% of all children suffering from a SSNS are frequently
relapsing or even steroid-dependent forms of NS [8,9]. Frequently relapsing nephrotic syndrome
(FRNS) is defined as more than four relapses in one year or more than two relapses following the
first six months after the initial presentation. Patients with at least two relapses during treatment
with alternate-day steroids or within 14 days after stopping steroid treatment are classified as
steroid-dependent (SDNS) [8,10]. Treatment of relapses is usually based on steroids with a shorter
duration (prednisone 60 mg/m2 until remission, 4 weeks 40 mg/m2 every other day) [5]. FRNS and
SDNS usually react quickly to treatment with glucocorticoids, and long-term prognosis regarding
renal function is very good [11], but patients suffer from relapses frequently and need to be treated
repeatedly. However, cushingoid changes, hyperglycemia, infection, abnormal bone metabolism, skin
atrophy, striae, peptic ulcer, adrenal suppression, increased blood pressure, and behavioral changes
are well-recognized, potentially serious adverse effects of corticosteroids [12–14].
Therefore, there is an increasing demand for alternative less harmful therapies. In the past, there
has been extensive evidence for the use of so-called steroid-sparing agents such as mycophenolic acid
(MPA), rituximab, alkylating agents like cyclophosphamide and calcineurin inhibitors, which have
been summarized and reviewed elsewhere [5,15]. Cyclophosphamide has bladder toxicity and other
side effects such as gonadal toxicity, bone marrow depression, carcinogenesis, and an increased risk of
infection [16]. Calcineurin inhibitors, cyclosporine and tacrolimus may lead to neurotoxicity, hirsutism,
gingival hyperplasia, and nephrotoxicity [17]. Mycophenolate mofetil (MMF) and MPA are newer
immunosuppressive drugs that have fewer serious adverse effect but have the disadvantage of high
therapy costs [18,19].
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The aim of this review is to focus on the use of levamisole, which seems to have a similar effect
with other substances, but exhibits a lower number of adverse events and reactions. Levamisole has
been considered the least toxic and least expensive steroid-sparing drug for preventing relapses of
SSNS. Therefore, the use of levamisole should always be taken into account. However, levamisole is
used in restricted areas (mostly in India and Europe). In FRNS and SDNS, levamisole significantly
reduces both the relapse rate and the cumulative steroid dose; therefore, it should be recommended for
these patients. In this review, we focus on the efficacy by critically discussing the literature, including
randomized controlled trials (RCT), observational studies and existing meta-analyses for levamisole in
order to highlight the usefulness and side effects of the drug, and the implications to treatment for
nephrotic syndrome.
3. The Use of Levamisole in the Treatment of Nephrotic Syndrome
Levamisole is an immune-modulating imidazothiol-derived anthelminthic. It was first used
in 1969 as an anthelmintic agent. In humans, levamisole was originally used in the treatment of
leprosy [20] and colonic carcinoma [21]. As a treatment of SSNS, it has been used since the early
1980s [22]. Besides a few uncontrolled levamisole studies [23,24], the first controlled study was
performed by the British Association of Pediatric Nephrology, published in 1991. In this study, a
significant reduction of disease relapses in children was demonstrated with the use of levamisole [25].
Data from Kemper et al. identified that patients with exclusively frequent relapses responded to
levamisole better than those with steroid dependence [26]. The Indian pediatric nephrology group
revised its guidelines of nephrotic syndrome so that levamisole could be used as a steroid-sparing
agent. The recommended dose is 2–2.5 mg/kg on alternate days for 12–24 months, while monitoring
leukocyte count every 12–16 weeks [27]. In 2017, Gruppen et al. published an international RCT. In this
double-blinded study, 99 children with SDNS and FRNS were treated with levamisole (2.5 mg/kg
on alternate days) or placebo. They found that there was a significantly longer time to the first
relapse in patients treated with levamisole compared to the placebo group [28]. Subgroup analysis
showed that cases with SDNS (mostly from Europe) had an inferior response to FRNS (mostly from
India). There are some considerations preferring levamisole in the treatment of FRNS over its use
in SDNS [20,29]. The authors discussed different genetic backgrounds and immunological changes
due to steroid dependency and preceding long-term steroid treatments, resulting in pharmacological
interactions [28,29]. Recently in an open-label RCT studying SDNS and FRNS, both MMF (76 patients
with 750–1000 mg/m2) and levamisole (73 patients with 2 to 2.5 mg/kg on alternate days) showed
similar relapse rates, treatment failure rates, disease course and decreased cumulative steroid dose [30].
As 2.5 mg/kg every other day is the historical dosage, more studies are needed to define the appropriate
dosage and duration of treatment [29].
There are several older RCTs, which were summarized in a Cochrane analysis published in
2013 [31]. When treatment with levamisole was compared to placebo, low-dose prednisone or no
treatment, there was a significant reduction of relapse numbers in children with SSNS. Several different
levamisole dosages have been employed in terms of total dose administrated (35 mg/m2/month vs.
20 mg/m2/month) or frequency (alternate day vs. 2 consecutive days of 7 days) [32]. The risk of
relapse during the treatment period decreased by up to 10–45% in various studies [33]. However, the
duration of treatment was relatively short; it varied from four to twelve months. Another observation
was that levamisole reduced the relapse rate only during the actual treatment period, and had no
significant impact on relapse risk after the discontinuation. Compared to intravenous, monthly [34]
or orally administered cyclophosphamide [31], there seems to be a slightly higher rate of relapse
during levamisole therapy. Nevertheless, there was no significant difference in the number of children
suffering from one or more relapses in the period between both treatments [24].
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In addition to these RCTs, there have been a lot of smaller retrospective studies in the last decade,
but most often only single center experiences have been published [35–40]. These papers stated that in
children with FRNS or SDNS [36–38,40], levamisole could be effective in decreasing relapse risk and
frequency. However, some of these studies used low-dose prednisolone or a slowly tapering regimen in
addition to 2–2.5 mg/kg body weight levamisole on alternate days [27]. Many of these studies showed
that levamisole lowered the number of relapses during the therapy period. Additionally, the use
of steroids and the total cumulative dosage were significantly reduced. Interestingly, in one study,
the relapse rate was even higher after the discontinuation of the treatment [39], whereas Elmas et al.
reported a reduced relapse risk 12 month after cessation of levamisole [40]. Basu and colleagues [39]
retrospectively analyzed the data from children who had received either levamisole or MMF or
tacrolimus. They verified that the relapse-free survival was higher after 30 months in patients treated
with tacrolimus or MMF compared to levamisole (61.7% vs. 38.5% vs. 24%). Nevertheless, levamisole
treatment resulted in a significant reduction in relapse rate compared to the relapse frequency in the
year before treatment.
Tables 1 and 2 summarized recent reports of levamisole for FRNS or SDNS in children and adults.
As stated above, levamisole has been commonly used at 2.5 mg/kg/day every other day (maximum
150 mg). In all studies, levamisole was given at a dose of 35 mg/kg/month (2–2.5 mg/kg/day every
other day), while a lower dosage seems to be less effective [31]. Some retrospective studies used
levamisole every day. Many observational studies have been conducted, mainly to show the reduction
of the recurrence rate in the treatment period after levamisole initiation compared with the time before
levamisole. Although not many RCTs and meta-analyses had yet been performed, these studies also
showed that levamisole reduced recurrence rate compared with placebo or steroid monotherapy. Some
RCTs showed that levamisole was not inferior to MMF and cyclophosphamide. A meta-analysis was
not sufficient to compare levamisole to MMF and cyclophosphamide (Table 3). We were not able to
provide any data on accurate dose, timing, and duration of levamisole. The pharmacokinetic profile in
children seems to be similar to the data available for adults, except for a documented slightly higher
clearance rate in children [41]. A French trial (NEPHROVIR 3, NCT02818738) comparing the effects of
levamisole with steroid at initial INS presentation for reducing relapse rate is currently ongoing.
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Table 1. Observational studies of steroid-dependent or frequent relapsing nephrotic syndrome treated with levamisole.
Author, Year StudyDesign
Comparison (Dose of
Levamisole)
Total
Patients Relapse (%) FU Other Effect
Tanphaichitr P, 1980 [22] Obs (1.5–3.9 mg/kg twice per week) 7 - 1–6 mo (33.5 ± 9.5 % vs. 69.3 ± 3.9%) a
Niaudet P, 1984 [42] Obs (2.5 mg/kg twice per week) 30 - 9.9 mo -
Mehta KP, 1986 [43] Obs (2.5 mg/kg qod or qd) 14 - 6–24 mo 6 Pts CR, 6 Pts PR
La Manna A, 1988 [44] Obs (2.5 mg/kg twice a week or qd) 13 - 7–29 mo b
Srivastava RN, 1991 [45] Obs (5 mg/kg qod) 12 Before L (3.3/yr), After L (2.3/yr) 3 mo -
Meregalli P, 1994 [46] Obs (5 mg/kg weekly) 10 Reduction SD 62–75% - -
Ksiazek J, 1995 [47] Obs - 22 18.2% relapse/36.4% not response - 45.5% remission maintained
Ginevri F, 1996 [48] Obs (2.5 mg/kg qod) 20 45.5% remission maintained after L,36.4% not respond to L - -
Bagga A, 1997 [23] Obs (2.5 mg/kg qod) 43 Before L (5.2/yr), After 2 years L (0.69/yr) 6–31 mo -
Kemper MJ, 1998 [26] Obs (2.0 mg/kg qod) 25 Prior to L 0.5/month,During L 0.3/month 3–24 mo -
Fu LS, 2000 [49] Obs (2–3 mg/kg qod) 27 Prior to L (5.74 ± 3.24/yr),During L (1.91 ± 2.0/yr) 6–24 mo -
Alsaran K, 2001 [50] Obs L (2.5 mg/kg) vs. CPA 24 L (0.28/month),CPA (0.32/month) -
c
Donia AF, 2002 [51] Obs (2.5 mg/kg qod) 20 25% in remission 12 mo,75% relapses during Tx 12 mo -
Al-Ibrahim AA, 2003 [52] Obs (2.5 mg/kg qod) 24 Prior to L (4/yr),During L (1.3/yr) 12–24 mo -
Sumegi V, 2004 [53] Obs (2 mg/kg qd) 34 Prior to L (4.41/yr),During L (0.41/yr) 24 mo
Cumulative steroid dose
7564 mg/yr vs. 1472 mg/yr
Fu LS, 2004 [54] Obs (2–3 mg/kg qod or qd) 36 qod 2.01 ± 2.5/yr,qd 1.34 ± 2.1/yr 4–36 mo -
Hafeez F, 2006 [55] Obs (2.5 mg/kg qod) 70 19 (27.14%) pts did not relapse on Tx 12 mo d
Boyer O, 2008 [37] Obs (2.5 mg/kg 3 days/week) 10 Prior to L (6.0/yr),During L (0.0/yr) 48 mo
e
Madani A, 2010 [38] Obs (2.5 mg/kg qod) 304 Prior to L (2.0/yr),During L (1.1/yr) 1–22 yrs
Steroid dose was significantly
reduced
Chen SY, 2010 [56] Obs (2–3.3 mg/kg qd) 15 1 pt CR, 10 pts No effect 3–20 mo -
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Table 1. Cont.
Author, Year StudyDesign
Comparison (Dose of
Levamisole)
Total
Patients Relapse (%) FU Other Effect
Elmas AT, 2013 [40] Obs (2.5 mg/kg 3 days/week) 29 Prior to L (4.0/yr),During L (0.0/yr) 12 mo Proteinuria, annual SD reduced
Ekambaram S, 2014 [35] Obs (2 mg/kg qd) 97 Prior to L (2.4/yr),During L (1.3/yr) 6–24 mo
Steroid dose (4.1 g/m2 to 2.5
g/m2)
Skrzypczyk P, 2014 [57] Obs (2.5 mg/kg/qd or qod or twice aweek) 21 - -
f
Jiang L, 2015 [58] Obs (1.25 mg/kg qd) 15 Adult 14 pts reduction or stopping othermedications 1–14 yrs
Kuzma-Mroczkowska E,
2016 [36] Obs (2.5 mg/kg qod) 53
Prior to L (2.7/yr),
During L (1.8/yr) 36 mo
8.8 mo to relapse on levamisole
Tx
Alsaran, K, 2017 [59] Obs (2.5 mg/kg qod) 20 Prior to L (3.6/yr),During L (1.6/yr) 12 mo
Cumulative steroid dose was
reduced
Abeyagunawardena, 2017
[60] Obs (2.5 mg/kg qod vs. qd) 58
L qod (163/yr),
L qd (77/yr) 12 mo
M annual SD (mg/kg/yr) qod
vs. qd (254 vs. 154)
Basu B, 2017 [39] Obs (2.5 mg/kg qod) 129 During L (1.7/yr)After L (2.8/yr) 30 mo
g
CPA: Cyclophosphamide, CR: complete response, FU: Follow up, L: Levamisole, M: mean, mo: months, Obs: observational study, PR: partial response, Pt: patient, qd: once daily, qod:
every other day, SD: steroid dose, Tx: treatment, yr: year. a % of E-rosette before and after levamisole; b Response rate: levamisole 2.5 mg twice a week-4 of the 13 patients, levamisole
2.5 mg qd-2 patients of the 8 patients; c Levamisole (0.28) and cyclophosphamide (0.32) showed no significant difference in reduction of relapse rate; d Levamisole was more effective in
older children (>5 years, vs. <5 years); e cumulative steroid 6067 mg/m2 to 2920 mg/m2; f Responder group was more frequently treated with steroid and levamisole and less frequently
treated with cyclosporine A; g The relapse free survival was higher with tacrolimus than levamisole (61.7% vs. 24%).
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Table 2. Randomized controlled trials of steroid-dependent or frequent relapsing nephrotic syndrome children treated with levamisole (RCT).
Author, Year Inclusion Exclusion Comparison TotalPatients/Control Relapse (%)
FU
Weeks
Effect Size
(RR, 95% CI)
BAPN, 1991 [25] SSNS NR L (2.5 mg/kg qod) + steroid vs.Placebo + steroid (16 weeks) 61/30
L 57% (17/31)
Placebo 87% (26/30) 16
0.63
(0.45–0.90)
Weiss, 1993 * [61] FRNS, SDNS Prior Tx with otherIS within 6mo
L (2.5 mg/kg twice a week) + steroid
vs. Placebo + steroid (6 mo) 48/26
L 95% (21/22)
Placebo 81% (21/26) 24
1.18
(0.96–1.46)
Dayal, 1994 [62] SSNS SRNS L (2–3 mg/kg twice a week) + steroidvs. steroid alone (48 weeks) 36/14
L 41% (9/22)
Steroid alone 71% (10/14) 48
0.57
(0.31–1.05)
Rashid, 1996 * [63] FRNS, SDNS NR L (2.5 mg/kg qod) + steroid vs.steroid alone (6 mo) 40/20
L 30% (6/20)
Steroid alone 60% (12/20) 44
0.50
(0.23–1.07)
Sural, 2001 * [64] FRNS, SDNS NR L (2.5 mg/kg qod) + steroid vs.steroid alone (6 mo) 58/28
L 27% (8/30)
Steroid alone 82% (23/28) 48
0.32
(0.17–0.60)
Donia, 2005 [34] SSNS NR L (2.5 mg/kg qod) + steroid vs. IVCPA + steroid 40/20
L 50% (10/20)
CPA 55% (11/20) 96
0.91
(0.50–1.64)
Al–Saran, 2006
[65] FRNS, SDNS Prior Tx with IS
L (2.5 mg/kg qod) + steroid vs.
steroid alone (1 yr) 56/24
Levamisole 9% (3/32)
Steroid alone 50% (12/24) 48
0.19
(0.06–0.59)
Abeyagunawardena
AS, 2006 * [66] SSNS NR L (2.5 mg/kg qod) + steroid vs. No Tx 76/34
L 19% (8/42)
Control 76% (26/34) 48
0.25
(0.13–0.48)
Gruppen, 2018 [28] FRNS, SDNS
Unresponsiveness
to cyclosporine or
MMF
L (2.5 mg/kg qod) + steroid vs.
Placebo (maximum 21 days) 99/49
L 66% (33/50)
Placebo 86% (42/49) 48
0.30
(0.11–0.82)
Sinha, 2019 [30] FRNS, SDNS Prior Tx with otherIS L (2–2.5 mg/kg qod) vs. MMF 149/76
L 66% (48/73)
MMF 59% (45/76) 48
0.79
(0.58–1.07)
BAPN: British Association for Pediatric Nephrology, CI: Confidence interval, CPA: Cyclophosphamide, FRNS: Frequently relapsing nephrotic syndrome, FU: Follow up,
IS: immunosuppressive agents, L: Levamisole, MMF: Mycophenolate mofetil, mo: months, NR: not reported, qod: every other day, qd: every day, RCT: randomized controlled trial,
RR: Risk ratio, SDNS: Steroid dependent nephrotic syndrome, SRNS: Steroid resistant nephrotic syndrome, SSNS: Steroid sensitive nephrotic syndrome, Tx: treatment, yr: year. * Data were
extracted from the abstract.
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Table 3. Summary of meta-analysis of RCTs on levamisole treatment in nephrotic syndrome.
Author, Year Comparison Outcome No. ofStudies
No. of
Cases/Controls
Type of
Metrics
Reported
Summary
Effect (95% CI)
Reported
p-Value
Largest
Effect
(95% CI)
I2
(p Value)
No. of
Significant
Study/Total
Study
Durkan AM, et al.
2001 [67]
L vs.
placebo
Relapse
(4–12 mo) 3 137/64 RR 0.60 (0.45–0.79) 0.0004
0.63
(0.45–0.90)
0.0%
(0.84) 1/3
Durkan AM, et al.
2005 [68]
L vs.
placebo/no
treatment
Relapse
(4–12 mo) 4 185/90 RR 0.71 (0.41–1.23) 0.23
0.63
(0.45–0.90)
86%
(<0.001) 1/4
Hodson EM, et al.
2008. [69]
L vs.
placebo
Relapse
(4–12 mo) 6 317/148 RR 0.50 (0.25–0.99) 0.046
0.25
(0.13–0.48)
92%
(0.046) 3/6
Hodson EM, et al.
2008 [69] L vs. IV CPA Relapse (E) 1 40/20 RR 0.91 (0.50–1.64) NA - - 0/1
Pravitsitthikul N,
et al. 2013 [31]
L vs.
steroids or
placebo or
both, or no
treatment
Relapse
(4–12 mo) 7 375/176 RR 0.47 (0.24–0.89) 0.021
0.25
(0.13–0.48)
92%
(<0.001) 4/7
Pravitsitthikul N,
et al. 2013 [31] L vs. IV CPA Relapse (E) 2 97/47 RR 2.14 (0.22–20.95) 0.51
7.20
(0.96–53.89)
79%
(0.03) 0/2
CPA: Cyclophosphamide, E: end of therapy, L: Levamisole, mo: months, NA: Significant, RCT: randomized controlled trial, RR: relative risk. Largest effect: Effect size (95% CI) and p-value
from the largest study in each meta-analysis.
J. Clin. Med. 2019, 8, 860 9 of 16
4. Known Side Effects of Levamisole Treatment
Levamisole is a U.S. Food and Drug Administration pregnancy category C drug. It was withdrawn
in the United States and Europe because of adverse effects (agranulocytosis and the risk of developing
anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis) and lack of clear indications [70].
However, the adverse effects of levamisole are mostly mild and transient, disappearing after its
discontinuation. Common adverse effects include gastrointestinal symptoms (nausea, abdominal
cramps), and pyrexia [71]. There were only a few serious adverse events documented in studies
focusing on iNS. Single cases of gastrointestinal disturbances [31,41] or leukopenia [25,31] have
been reported in the RCTs, probably caused by the use of levamisole. Most retrospective studies
reported no side effects of levamisole [37,39,40], or only minor reversible effects such as rash, fever,
abdominal pain, elevated liver enzymes, neutropenia or thrombocytopenia, which all disappeared
after cessation of levamisole [36,52]. In their placebo-controlled multi-centric trial, Gruppen et al.
showed that the use of levamisole was safe [28]. However, the definition of leukopenia was different
in each study. In addition, recent studies have reported adverse events as neutropenia instead of
leukopenia. Therefore, there is a clear limitation related to reporting all reported adverse effects
together. Nevertheless, a comprehensive examination of reported studies indicates that the incidence
of leukopenia varies from 0 to 20%. Of the 1391 cases that reported adverse effects of levamisole,
51 cases (leukopenia or neutropenia) had leukopenia (3.7%) (Table 4). This seems not much different
from the incidence reported in other diseases [72]. Leukopenia related to the use of levamisole
was spontaneously reversible after discontinuation of the treatment [28]. Levamisole can cause a
variety of dermatologically adverse effects. It can cause lichenoid eruption, fixed dug eruptions,
leg ulcers, purpura of the ears, and cutaneous necrosis [72]. Like other adverse events, symptoms
resolved when levamisole treatment was stopped. In addition, leukoencephalopathy, skin necrosis,
hyponatremia, acute coronary syndrome, pulmonary hypertension, granulomatosis with polyangiitis
(GPA), and pyoderma gangrenosum were reported in single cases [73]. As levamisole is adulterated
with cocaine, it may be used on the “black market” to enhance cocaine effects. The frequency of
levamisole-induced GPA is increasing in the literature, with the proposed mechanisms having been
recently highlighted [74].
Table 4. Reported side effects of levamisole in nephrotic syndrome.
Author, Year Levamisole Dose Number Leukopenia GIUpset
Skin
Rash Arthritis Other
BAPN, 1991 [25] 2.5 mg/kg qod 31 0 1 0 0 0
Weiss, 1993 * [61] 2.5 mg/kg twice a week 22 0 0 0 0 0
Sural, 2001 * [64] 2.5 mg/kg qod 30 1 0 0 0 0
Donia, 2005 [34] 2.5 mg/kg qod 20 0 0 0 0 14 a
Al-Saran, 2006 [65] 2.5 mg/kg qod 32 0 1 0 0 0
Gruppen, 2018 [28] 2.5 mg/kg qod 50 8 1 0 1 26 b
Sinha, 2019 [30] 2–2.5 mg/kg qod 73 0 18 2 0 0
Tanphaichitr P, 1980 [22] 1.5–3.9 mg/kg twice a week 7 0 0 0 0 0
Niaudet P, 1984 [42] 2.5 mg/kg twice a week 30 7 0 0 0 0
Metha KP, 1986 [43] 2.5 mg/kg qod 14 0 3 1 0 2 c
La Manna A, 1988 [44] 2.5 mg/kg qd 13 0 1 1 0 1 d
Prandota J, 1989 [75] 2.1–3.1 mg/kg qd 6 0 0 0 0 6 e
Srivastava RN, 1991 [45] 5 mg/kg qod 12 1 0 1 0 0
Meregalli P, 1994 [46] 5 mg/kg weekly 10 1 0 1 0 0
Bagga A, 1997 [23] 2.5 mg/kg qod 43 0 0 0 0 0
Kemper MJ, 1998 [26] 2.0 mg/kg qod 25 2 1 1 0 0
Fu LS, 2000 [49] 2-3 mg/kg qod 27 7 0 0 0 0
Alsaran K, 2001 [50] 2.5 mg/kg qod 24 0 0 1 0 0
Donia AF, 2002 [51] 2.5 mg/kg qod 20 0 0 0 0 0
Al-Ibrahim AA, 2003 [52] 2.5 mg/kg qod 24 1 2 2 0 0
Sumegi V, 2004 [53] 2 mg /kg qd 34 5 0 0 0 0
Fu LS, 2004 [54] 2–3 mg/kg qd or qod 36 9 0 0 0 0
Hafeez F, 2006 [55] 2.5 mg/kg qod 70 0 0 0 0 0
Boyer O, 2008 [37] 2.5 mg/kg twice a week 10 0 0 0 0 0
Madani A, 2010 [38] 2.5 mg/kg qod 304 1 0 0 0 1 f
Elmas AT, 2013 [40] 2.5 mg/kg twice a week 29 0 0 0 0 0
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Table 4. Cont.
Author, Year Levamisole Dose Number Leukopenia GIUpset
Skin
Rash Arthritis Other
Ekambaram S, 2014 [35] 2 mg/kg qd 97 0 0 0 0 0
Jiang L, 2015 [58] 1.25 mg/kg qod 15 3 2 2 0 0
Kuzma-Mroczkowska,2016 [36] 2.5 mg/kg qod 53 1 3 9 0 6 g
Alsaran K, 2017 [59] 2.5 mg/kg qod 20 4 0 0 0 0
Abeyagunawardena AS, 2017 [60] 2.5 mg/kg qd and qod 58 0 0 0 0 0
Basu B, 2017 [39] 2.5 mg/kg qod 129 0 0 0 0 3 h
Youssef DM, 2018 [76] 2.5 mg/kg qod 23 0 0 0 0 0
Total 1391 51(3.7%)
33
(2.4%)
21
(1.5%)
1
(0%)
59
(4.2%)
BAPN: British Association for Pediatric Nephrology, GI: gastrointestinal, qd: once daily, qod: every other day.
a Respiratory infection (9), Scalp infection (2), Urinary tract infection (1), sialadenitis (1), personality change (1).
b Cough (6), Nasopharyngitis (8), Pyrexia (10), ANCA-associated vasculitis (1), Reduced glomerular filtration
rate (GFR) (1). c Transient hematuria (2). d Allergic conjunctivitis (1). e Thrombocytopenia (4), elevated liver
transaminases (2). f Vertigo (1). g Elevated liver transaminases (3), arthralgia (2), thrombocytopenia (1). h Malaria
(2), transient mood change (1). * Data were extracted from the abstract.
Recent studies showed almost the same effect in adults with iNS [58]. Both KDIGO and Cochrane
recommend levamisole with evidence grade 1b as an alternative medication to reduce the steroid load
of patients with frequently relapsing iNS [69,77]. However, the precise pharmaceutical mechanism of
this drug still needs to be evaluated. In addition, levamisole is used at a similar dose (2.0–2.5 mg/kg
on alternate days, maximum 150 mg) to treat other diseases in adults [20,21,72], but few studies have
investigated its efficacy in the management of nephrotic syndrome.
5. Mechanism Hypothesis
Proteinuria in nephrotic syndrome has been linked to various mechanistic dysfunctions in
podocytes, leading to podocyte foot process effacement. MCNS is a pathological condition, which
is characterized by subtle glomerular lesions causing massive and reversible proteinuria that is
usually steroid sensitive. Glucocorticoids have historically been used as a first-line therapy in MCNS
on the basis of their immunosuppressive function. However, it has been shown that podocytes
serve as non-immunologic targets for several immunosuppressive drugs like cyclosporine and
glucocorticoids [78]. Th2 cytokines (Interleukin (IL)-13, IL-4, IL-5) are increased in patients with
nephrotic syndrome, and changes in vascular permeability have been reported, which are both involved
in the complex pathogenesis of proteinuria in nephrotic syndrome [3,79–81]. Lai et al. showed that IL-13
transfected rats showed increased levels of proteinuria, raised serum cholesterol and decreased serum
albumin levels and podocyte foot processes showed fusion mimicking MCNS [82]. The podocyte’s
actin cytoskeleton is a discovered target for newer therapies. Calcineurin inhibitors, for example,
block the dephosphorylation of the cytoskeleton component synaptopodin, and steroids increase actin
polymerization and stability [83,84].
Levamisole is a synthetic imidazole derivative, which was used for its anthelmintic effects by
acting as a nicotinic acetylcholine receptor agonist. Because various adverse effects including severe
agranulocytosis in animals have been reported, levamisole is no longer used to treat any parasitic
infections. Levamisole increases lymphocyte cyclic guanosine monophosphate (cGMP) by affecting
cholinergic activity on T lymphocyte. Increased adenosine deaminase and free radicals act on both T
and B lymphocytes. However, this drug has an additional immune-modulating action. It induces type 1
(Th1) and type 2 (Th2) immune responses through enhancing IL-18 activity [3]. It is also known that
an enhanced Th1 or Th2 immune response is associated with several inflammatory and autoimmune
diseases, such as SLE [85], asthma [86,87] and type 1 diabetes [88]. Therefore, levamisole is thought
to have immunomodulatory potential. Szeto and colleagues showed that treatment with levamisole
leads to a shift in the immune response in Brown Norway rats. This caused the augmentation of
Th1 response and reduced the Th2 response [89]. Its effect is more pronounced on T lymphocyte
than on B lymphocytes. Increased CD4+T/CD8+T Cell ratio and reduced IL-4 have been observed
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in levamisole-treated lichen planus patients and in a mouse model [87,90]. Experimental studies
have shown that in mice with allergic rhinitis levamisole decreased IL-4, IL-5, and IL-13 mRNA and
at the same time enhanced the expression of IL-12, IL-18 and interferon (IFN)-gamma mRNA [71].
IL-13 is an important Th2 cytokine involved in the induction of MCNS in a rat experiment model
by the down-regulation of nephrin, podocin, and dystroglycan. It can also up-regulate B7-1 [65],
and is altering the expression of zonula occludens-1 (ZO-1) in human podocytes [91]. In summary,
the beneficial effect of levamisole on MCNS might be due to its suppressing effect on IL-13 expression.
Upregulation of T helper-1 (Th1) cells and down-regulation of Th2 cells is considered to be the main
mechanism for treating FRNS or SDNS patients [30,90,92]. Levamisole reduces immunoglobulin
(IG) G, IG M, and circulating immune complex, which inhibit B cell activity [93]. Activated B cells
caused podocyte foot process effacement via IL-4 [81]. In addition, total B cell increased in pediatric
SSNS patients [94]. Although more mechanisms are still needed, not only T cells, but also B cells are
considered to be therapeutic targets of levamisole.
Recent work has shown an additional direct effect of levamisole on podocytes. In an immortalized
human podocyte culture, the authors were able to show that levamisole enhanced the expression and
activity of the glucocorticoid receptor (GR). GR is present in glomerular cells including podocytes.
Furthermore, levamisole protected podocytes in a puromycin aminonucleoside (PAN)-treated cell
model. In this model, the effectiveness of levamisole is blocked by the GR antagonist mifepristone
(RU486), suggesting that GR signaling is a critical target of levamisole’s action. Activated GR restoration
of Bcl-2 and reduction of p53 in PAN treated podocytes resulting in inhibition of podocyte apoptosis [95].
Another study has shown that activated GR upregulates the expression of nephrin and Rho-A, leading
to enhanced actin filament stability [96,97]. These data indicate that levamisole might be effective in
nephrotic syndrome in adults as well as in children [58]. Those effects of levamisole are presented in
Figure 1.
In summary, there is no universally accepted explanation how levamisole works in SSNS.
Levamisole-induced changes in the immune-mediated response may cause reduction of relapses in
predominantly immune mediated diseases. This may be one explanation for its ineffectiveness in cases
of steroid-resistant nephrotic syndrome [98].
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Figure 1. The summary effects of levamisole in iNS. Bcl2: B-cell lymphoma 2, CD: Cluster of
differentiation, IFN-γ: interferon gamma, IL: interleukin, iNS: idiopathic nephrotic syndrome, GCR:
glucocorticoid receptor, p53: tumor protein p53, Th Cell: The T helper cells.
6. Summary and Conclusions
The effect of immunosuppressive agents in proteinuric glomerular diseases is attributed to
immune-dependent mechanisms. However, recent studies have revealed that the anti-proteinuric
effect of commonly used drugs might be related not only to their immunosuppressive actions, but
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also occur via a direct effect on podocytes. This also includes levamisole. Levamisole seems to be
effective in reducing the risk of disease relapses in steroid sensitive forms of NS. In the reported
studies, few serious side effects have been reported, compared to other steroid-sparing agents. There
are hints that it is less effective compared to cyclophosphamide [34,69] and compared to MMF [39],
but in comparison to both of these drugs, the adverse effects spectrum is beneficial. However, RCTs
comparing different steroid-sparing agents head to head with levamisole in the treatment of SSNS
are still lacking. Given the low frequency of side effects and that most adverse events improve with
discontinuation of levamisole and KDIGO recommendations [77], levamisole could be a valuable
alternative therapy for patients having frequent relapsing iNS. In addition, it has been shown that even
after discontinuation of levamisole, long-term remission can be achieved. Therefore, levamisole should
be considered a precious option in the treatment of SSNS, especially in cases of contraindications for
immunosuppressive drugs. Regular monitoring of white blood count cells, renal function and testing
of ANCA is advised in cases reporting symptoms of vasculitis.
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